secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2022-06-06T23:59:59+00:00
Accession:  0001628280-22-016371
Event type: other_material
Sentiment:  negative
Materiality: 0.55
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead retains three directors who failed to win majority vote at 2022 annual meeting
--------------------------------------------------------------------------------

- Directors Perry, Ferrari, and Waddill each received less than a majority of votes for re-election on March 17, 2022.
- The Nominating Committee and Board unanimously rejected their resignation offers, citing qualifications and board composition.
- Primary reason for vote outcome was shareholder concern over executive compensation programs.
- All three directors will continue serving until the 2023 annual meeting or until successors are elected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828022016371/0001628280-22-016371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828022016371/arwr-20220601.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-016371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer